

July 30, 2019

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Unaudited Financial Results for the quarter ended June 30, 2019

Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Unaudited Financial Results for the quarter ended June 30, 2019 which were approved by the Board of Directors of the Company, at its meeting held on July 30, 2019 along with Limited Review Report issued by the Statutory Auditors of the Company.

The meeting commenced at 11:00 a.m. and concluded at 2.00 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: As above

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review report on Quarterly Standalone Financial Results of RPG Life Sciences Limited Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

The Board of Directors of RPG Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited financial results of RPG Life Sciences Limited ('the Company') for the quarter ended 30 June 2019 ('the statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full year ended 31 March 2019 ("previous financial year") and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Limited Review report on Quarterly Standalone Financial Results of RPG Life Sciences Limited Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (Continued)

RPG Life Sciences Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W- 100022



Mumbai
30 July 2019

Bhavesh Dhupelia
Partner
Membership No: 042070
UDIN: 19042070AAAABO5459

(Rs. in Lakhs)

Statement of Financial Results for the quarter ended 30th June 2019


Particulars	Quarter ended			Year ended
	30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from Operations	9,404	6,880	7,989	33,016
2 Other Income	16	42	39	80
3 Total Income	9,420	6,922	8,028	33,096
4 Expenses				
(a) Cost of Materials Consumed	1,677	953	1,511	5,117
(b) Purchases of Stock-in-Trade	1,134	1,212	1,215	4,516
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	462	159	(250)	1,371
(d) Employee Benefits Expense	2,312	1,991	2,222	8,993
(e) Finance Costs	73	91	104	399
(f) Depreciation and Amortisation Expense	392	394	371	1,532
(g) Other Expenses	2,284	1,910	2,597	9,663
Total Expenses	8,334	6,710	7,770	31,591
5 Profit before tax	1,086	212	258	1,505
6 Income tax expenses				
a. Current Tax	300	18	61	284
b. Deferred Tax	(49)	40	14	140
7 Profit for the period	835	154	183	1,081
8 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(10)	(23)	(6)	(41)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	3	8	2	14
Other Comprehensive Income Net of Tax	(7)	(15)	(4)	(27)
9 Total Comprehensive Income for the period	828	139	179	1,054
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				14,727
12 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):				
(a) Basic	5.05	0.93	1.11	6.54
(b) Diluted	5.05	0.93	1.11	6.54

Notes:

- The above results have been reviewed by the Audit Committee on July 29, 2019 and approved by the Board of Directors at its meeting held on July 30, 2019.
- The figures for the quarter ended March 31, 2019 are the balancing figures between the audited financial results for the year ended March 31, 2019 and the published unaudited financial results for the nine months ended December 31, 2018 which were subjected to a limited review.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Effective April 1, 2019 the Company has adopted Ind AS 116 "Leases" using modified retrospective approach. This has resulted in recognising right of use assets and lease liability as on April 1, 2019. The adoption of the standard did not have any material impact to the financial results.



For RPG Life Sciences Limited



Yugal Sikri
 Managing Director
 Mumbai, July 30, 2019